Skip to Main Content

Advertisement

Skip Nav Destination

Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression

Blood Adv (2020) 4 (8): 1628–1639.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement